CS
TOVX icon

Credit Suisse’s Theriva Biologics TOVX Stock Holding History

Credit Suisse’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed -$10K – 3955
2017
Q1 		$10K Sell
2
-2
-50% -$14K ﹤0.01% 3776
2016
Q4 		$29K Buy
4
+1
+33% +$10.3K ﹤0.01% 4055
2016
Q3 		$49K Sell
3
-1
-25% -$15K ﹤0.01% 4023
2016
Q2 		$58K Sell
4
-18
-82% -$339K ﹤0.01% 4137
2016
Q1 		$459K Buy
22
+15
+214% +$225K ﹤0.01% 3291
2015
Q4 		$141K Buy
+7
New +$148K ﹤0.01% 4010
2015
Q2 		– Sell
-11
Closed -$213K – 4636
2015
Q1 		$213K Buy
+11
New +$196K ﹤0.01% 4050
2014
Q2 		– Sell
-8
Closed -$176K – 4802
2014
Q1 		$176K Buy
+8
New +$166K ﹤0.01% 4395

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Credit Suisse's TOVX Position: Q2 2017 in Review

Credit Suisse sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 2 shares — an estimated $10K sold.

Credit Suisse first reported a position in TOVX in Q1 2014 and held it in 8 quarters. The position peaked at $459K in Q1 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Credit Suisse reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Credit Suisse sold 2 Theriva Biologics shares in Q2 2017, an estimated $10K.
  • Credit Suisse first reported a position in Theriva Biologics in Q1 2014 and held it in 8 quarters.
  • Credit Suisse's Theriva Biologics position peaked at $459K in Q1 2016.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Credit Suisse's 13F filing for Q2 2017, filed 14 Aug 2017.